SCHEMBL4686166

SCHEMBL4686166

O=C(O)N(Cc1cc(-c2ccc(F)c(F)c2)no1)c1ccon1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.40
MAPT P10636 2/20 0.39
THRB P10828 1/20 0.39
TP53 P04637 1/20 0.36
NOTUM Q6P988 3/20 0.35
POLB P06746 1/20 0.35
JAK2 O60674 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTPN1 P18031 2/20 0.34
WNT3A P56704 1/20 0.33
LMNA P02545 1/20 0.33
CSGALNACT1 Q8TDX6 1/20 0.33
HPGD P15428 1/20 0.33
KDM5A P29375 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
CYP11B1 P15538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680702 0.90 NOTUM (0.35) TP53NOTUMPOLBJAK2ALDH1A1
SCHEMBL4684216 0.85 MAPT (0.36) KMOMAPTTHRBTP53NOTUM
SCHEMBL4740687 0.77 MAPT (0.37) KMOMAPTTHRBTP53POLB
SCHEMBL4680699 0.72 POLB (0.48) MAPTTHRBTP53POLBJAK2
SCHEMBL4683349 0.71 NOTUM (0.66) MAPTTHRBTP53NOTUMPOLB
SCHEMBL6403916 0.71 NPC1 (0.50) NOTUMALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL3582885 0.69 IGF1R (0.46) MAPTTHRBTP53NOTUMPOLB
SCHEMBL6409336 0.68 NOTUM (0.55) MAPTNOTUMPOLBJAK2ALDH1A1
SCHEMBL4684429 0.68 NOTUM (0.66) MAPTTHRBTP53NOTUMPOLB
SCHEMBL3591952 0.68 POLB (0.72) MAPTTHRBTP53POLBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1437349-B9 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2008-09-10 EP disclosed
EP-1437349-B1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS S A L V A T LAB SA (ES) 2007-08-15 EP disclosed
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-01-20 US disclosed
EP-1437349-A1 SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014806-A1 Substituted isoxazoles and their use as antibiotics XDH, SCO2, HAX1 KMO 477/4885MAPT 4610/4885THRB 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.